Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures
Open Access
- 2 February 2022
- journal article
- research article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (4) , e202101116
Abstract
Background: There are limited effective prophylactic/early treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral entry requires spike protein binding to the angiotensin-converting enzyme-2 receptor and cleavage by transmembrane serine protease 2 (TMPRSS2), a cell surface serine protease. Targeting of TMPRSS2 by either androgen blockade or direct inhibition is in clinical trials in early SARS-CoV-2 infection. Methods: We used differentiated primary human airway epithelial cells at the air–liquid interface to test the impact of targeting TMPRSS2 on the prevention of SARS-CoV-2 infection. Results: We first modelled the systemic delivery of compounds. Enzalutamide, an oral androgen receptor antagonist, had no impact on SARS-CoV-2 infection. By contrast, camostat mesylate, an orally available serine protease inhibitor, blocked SARS-CoV-2 entry. However, oral camostat is rapidly metabolised in the circulation, with poor airway bioavailability. We therefore modelled local airway administration by applying camostat to the apical surface of differentiated airway cultures. We demonstrated that a brief exposure to topical camostat effectively restricts SARS-CoV-2 infection. Conclusion: These experiments demonstrate a potential therapeutic role for topical camostat for pre- or post-exposure prophylaxis of SARS-CoV-2, which can now be evaluated in a clinical trial.Keywords
All Related Versions
Funding Information
- Addenbrooke’s Charitable Trust (15/20A)
- NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
- Wellcome Trust (084957/Z/08/Z, Professor PJ Lehner)
- Medical Research Council (MR/V011561/1, Professor PJ Lehner)
- NC3Rs (NC/S001204/1, Dr Frank McCaughan)
- Roy Castle Lung Cancer Foundation (2015/10/McCaughan, Dr Frank McCaughan)
This publication has 48 references indexed in Scilit:
- TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike ProteinJournal of Virology, 2014
- Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacityRespiratory Research, 2013
- Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2Journal of Virology, 2013
- Reduced Sodium Transport With Nasal Administration of the Prostasin Inhibitor Camostat in Subjects With Cystic FibrosisChest, 2013
- Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating ProteaseThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Airway Epithelial Cells: Current Concepts and ChallengesProceedings of the American Thoracic Society, 2008
- A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer GrowthMolecular Cell, 2007
- ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway EpitheliaJournal of Virology, 2005
- Estimation of nasal epithelial lining fluid using urea as a markerJournal of Allergy and Clinical Immunology, 1993
- Nasal transit time in normal subjects and pathologic conditionsOtolaryngology–Head and Neck Surgery, 1990